Introduction: Recently, several mindfulness-based programs showed promising clinical effects in the treatment of psychiatric disorders including substance use disorders. However, very little is known about the effects of mindfulness-based interventions (MBIs) on brain structure in such patients. Methods: This study aimed to detect changes in gray matter volume (GMV) in opioid-dependent patients receiving MBI during their first month of treatment. Thirty patients were assigned to either 3 weeks of MBI (n = 16) or treatment as usual (TAU, n = 14) and were investigated using structural magnetic resonance imaging before and after treatment. Longitudinal pipeline of the Computational Anatomy Toolbox for SPM (CAT12) was used to detect significant treatment-related changes over time. The identified GMV changes following treatment were related to clinically relevant measures such as impulsivity, distress tolerance, and mindfulness. Results: After treatment, increased mindfulness scores were found in individuals receiving MBI compared to TAU. In the MBI group, there were also significant differences with respect to distress tolerance and impulsivity. Effects on mindfulness, distress tolerance, and impulsivity were also found in the TAU group. Longitudinal within-group analysis revealed increased left anterior insula GMV in individuals receiving MBI. Anterior insula volume increase was associated with decreased impulsivity levels. In the TAU group, significant GMV changes were found in the right lingual gyrus and right entorhinal cortex. Discussion/Conclusion: MBI can yield significant clinical effects during early abstinence from opioid dependence. MBI is particularly associated with increased insula GMV, supporting an important role of this region in the context of MBI-induced neural changes.

1.
Kabat-Zinn J, Lipworth L, Burney R. The clinical use of mindfulness meditation for the self-regulation of chronic pain.
J Behav Med
. 1985 Jun;8(2):163–90.
2.
Young KS, van der Velden AM, Craske MG, Pallesen KJ, Fjorback L, Roepstorff A, et al. The impact of mindfulness-based interventions on brain activity: a systematic review of functional magnetic resonance imaging studies.
Neurosci Biobehav Rev
. 2018 Jan;84:424–33.
3.
Goldberg SB, Tucker RP, Greene PA, Davidson RJ, Wampold BE, Kearney DJ, et al. Mindfulness-based interventions for psychiatric disorders: a systematic review and meta-analysis.
Clin Psychol Rev
. 2018 Feb;59:52–60.
4.
Li W, Howard MO, Garland EL, McGovern P, Lazar M. Mindfulness treatment for substance misuse: a systematic review and meta-analysis.
J Subst Abuse Treat
. 2017 Apr;75:62–96.
5.
Tang YY, Holzel BK, Posner MI. The neuroscience of mindfulness meditation.
Nat Rev Neurosci
. 2015 Apr;16(4):213–25.
6.
Fox KCR, Nijeboer S, Dixon ML, Floman JL, Ellamil M, Rumak SP, et al. Is meditation associated with altered brain structure? A systematic review and meta-analysis of morphometric neuroimaging in meditation practitioners.
Neurosci Biobehav Rev
. 2014 Jun;43:48–73.
7.
Vignaud P, Donde C, Sadki T, Poulet E, Brunelin J. Neural effects of mindfulness-based interventions on patients with major depressive disorder: a systematic review.
Neurosci Biobehav Rev
. 2018 May;88:98–105.
8.
Priddy SE, Howard MO, Hanley AW, Riquino MR, Friberg-Felsted K, Garland EL. Mindfulness meditation in the treatment of substance use disorders and preventing future relapse: neurocognitive mechanisms and clinical implications.
Subst Abuse Rehabil
. 2018;9:103–14.
9.
Fahmy R, Wasfi M, Mamdouh R, Moussa K, Wahba A, Wittemann M, et al. Mindfulness-based interventions modulate structural network strength in patients with opioid dependence.
Addict Behav
. 2018 Jul;82:50–6.
10.
Stahl B., Goldstein E.
Mindfulness-Based Stress Reduction Workbook
. Oakland, CA: New: Harbinger Publications, Inc; 2010.
11.
Qassem T, Beshry Z, Assad T, Omara A, Abdel Mawgoud M.
Profiles of neuropsychological dysfunction in chronic herion users
. Egypt: Faculty of medicineAin Shams University; 2003.
12.
McLellan AT, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The addiction severity index.
J Nerv Ment Dis
. 1980 Jan;168(1):26–33.
13.
Simons JS, Gaher RM. The distress tolerance scale: development and validation of a self-report measure.
Motiv Emot
. 2005;29(2):83–102.
14.
Whiteside SP, Lynam DR. Understanding the role of impulsivity and externalizing psychopathology in alcohol abuse: application of the UPPS impulsive behavior scale.
Exp Clin Psychopharmacol
. 2003 Aug;11(3):210–7.
15.
Walach H, Buchheld N, Buttenmüller V, Kleinknecht N, Schmidt S. Measuring mindfulness--the Freiburg Mindfulness Inventory (FMI).
Personal Individual Differ
. 2006;40(8):1543–55.
16.
Worsley KJ, Marrett S, Neelin P, Vandal AC, Friston KJ, Evans AC. A unified statistical approach for determining significant signals in images of cerebral activation.
Hum Brain Mapp
. 1996;4(1):58–73.
17.
Holzel BK, Ott U, Gard T, Hempel H, Weygandt M, Morgen K, et al. Investigation of mindfulness meditation practitioners with voxel-based morphometry.
Soc Cogn Affect Neurosci
. 2008 Mar;3(1):55–61.
18.
Gotink RA, Meijboom R, Vernooij MW, Smits M, Hunink MGM. 8-weeks mindfulness based stress reduction induces brain changes similar to traditional long-term meditation practice: a systematic review.
Brain Cogn
. 2016 Oct;108:32–41.
19.
Lazar SW, Kerr CE, Wasserman RH, Gray JR, Greve DN, Treadway MT, et al. Meditation experience is associated with increased cortical thickness.
Neuroreport
. 2005 Nov 28;16(17):1893–7.
20.
Holzel BK, Ott U, Hempel H, Hackl A, Wolf K, Stark R, et al. Differential engagement of anterior cingulate and adjacent medial frontal cortex in adept meditators and non-meditators.
Neurosci Lett
. 2007 Jun 21;421(1):16–21.
21.
Murakami H, Nakao T, Matsunaga M, Kasuya Y, Shinoda J, Yamada J, et al. The structure of mindful brain.
PLoS One
. 2012;7(9):e46377.
22.
Craig ADB. Significance of the insula for the evolution of human awareness of feelings from the body.
Ann N Y Acad Sci
. 2011 Apr;1225:72–82.
23.
Fleming SM, Dolan RJ. The neural basis of metacognitive ability.
Philos Trans R Soc Lond B Biol Sci
. 2012 May 19;367(1594):1338–49.
24.
Critchley HD, Wiens S, Rotshtein P, Ohman A, Dolan RJ. Neural systems supporting interoceptive awareness.
Nat Neurosci
. 2004 Feb;7(2):189–95.
25.
Gard T, Taquet M, Dixit R, Holzel BK, de Montjoye YA, Brach N, et al. Fluid intelligence and brain functional organization in aging yoga and meditation practitioners.
Front Aging Neurosci
. 2014;6:76.
26.
Gard T, Taquet M, Dixit R, Holzel BK, Dickerson BC, Lazar SW. Greater widespread functional connectivity of the caudate in older adults who practice kripalu yoga and vipassana meditation than in controls.
Front Hum Neurosci
. 2015;9:137.
27.
Zeidan F, Emerson NM, Farris SR, Ray JN, Jung Y, McHaffie JG, et al. Mindfulness meditation-based pain relief employs different neural mechanisms than placebo and sham mindfulness meditation-induced analgesia.
J Neurosci
. 2015 Nov 18;35(46):15307–25.
28.
Mackey S, Allgaier N, Chaarani B, Spechler P, Orr C, Bunn J, et al. Mega-analysis of gray matter volume in substance dependence: general and substance-specific regional effects.
Am J Psychiatry
. 2019 Feb 1;176(2):119–28.
29.
Naqvi NH, Rudrauf D, Damasio H, Bechara A. Damage to the insula disrupts addiction to cigarette smoking.
Science
. 2007 Jan 26;315(5811):531–4.
30.
Craig AD. How do you feel? Interoception: the sense of the physiological condition of the body.
Nat Rev Neurosci
. 2002 Aug;3(8):655–66.
31.
Paulus MP, Tapert SF, Schulteis G. The role of interoception and alliesthesia in addiction.
Pharmacol Biochem Behav
. 2009 Nov;94(1):1–7.
32.
Xu L, Groth KM, Pearlson G, Schretlen DJ, Calhoun VD. Source-based morphometry: the use of independent component analysis to identify gray matter differences with application to schizophrenia.
Hum Brain Mapp
. 2009 Mar;30(3):711–24.
33.
Kasparek T, Marecek R, Schwarz D, Prikryl R, Vanicek J, Mikl M, et al. Source-based morphometry of gray matter volume in men with first-episode schizophrenia.
Hum Brain Mapp
. 2010 Feb;31(2):300–10.
34.
Naqvi NH, Bechara A. The insula and drug addiction: an interoceptive view of pleasure, urges, and decision-making.
Brain Struct Funct
. 2010 Jun;214(5–6):435–50.
35.
Dalley JW, Robbins TW. Fractionating impulsivity: neuropsychiatric implications.
Nat Rev Neurosci
. 2017 Feb 17;18(3):158–71.
36.
Noel X, Brevers D, Bechara A. A neurocognitive approach to understanding the neurobiology of addiction.
Curr Opin Neurobiol
. 2013 Aug;23(4):632–8.
37.
Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis.
Lancet Psychiatry
. 2016 Aug;3(8):760–73.
38.
Ibrahim C, Rubin-Kahana DS, Pushparaj A, Musiol M, Blumberger DM, Daskalakis ZJ, et al. The insula: a brain stimulation target for the treatment of addiction.
Front Pharmacol
. 2019;10:720.
39.
Romer Thomsen K, Callesen MB, Hesse M, Kvamme TL, Pedersen MM, Pedersen MU, et al. Impulsivity traits and addiction-related behaviors in youth.
J Behav Addict
. 2018 Jun 1;7(2):317–30.
40.
Dambacher F, Sack AT, Lobbestael J, Arntz A, Brugman S, Schuhmann T. Out of control: evidence for anterior insula involvement in motor impulsivity and reactive aggression.
Soc Cogn Affect Neurosci
. 2015 Apr;10(4):508–16.
41.
Singh NN, Wahler RG, Adkins AD, Myers RE; Mindfulness Research Group. Soles of the feet: a mindfulness-based self-control intervention for aggression by an individual with mild mental retardation and mental illness.
Res Dev Disabil
. 2003 May–Jun;24(3):158–69.
42.
Friese M, Messner C, Schaffner Y. Mindfulness meditation counteracts self-control depletion.
Conscious Cogn
. 2012 Jun;21(2):1016–22.
43.
Takehara-Nishiuchi K. Entorhinal cortex and consolidated memory.
Neurosci Res
. 2014 Jul;84:27–33.
44.
Fahmy R, Wasfi M, Mamdouh R, Moussa K, Wahba A, Schmitgen MM, et al. Mindfulness-based therapy modulates default-mode network connectivity in patients with opioid dependence.
Eur Neuropsychopharmacol
. 2019 May;29(5):662–71.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.